$ORKA

3 stories mentioning ORKA

Every FINWIRES story that references ORKA, newest first.

Halozyme, Oruka Therapeutics Sign Licensing Agreement for Microparticle Drug Delivery Platform

Halozyme (HALO) said Wednesday its Hypercon unit entered into an agreement with Oruka Therapeutics (ORKA) on exclusive rights to use a specialized microparticle drug platform for an experimental psoriasis treatment and up to one additional target.The transaction requires an immediate upfront payment, potential future milestone payments, and ongoing mid-single-digit royalties based on future commercial product sales, the company said.The system allows biologic drugs to be more highly concentrated, shrinking the required injection volume and making dosing easier, Halozyme said.Price: $66.17, Change: $+0.30, Percent Change: +0.46%

$HALO$ORKA

Insider Trading42d ago

Oruka Therapeutics Insider Sold Shares Worth $319,384, According to a Recent SEC Filing

Laura Lee Sandler, Chief Operating Officer, on May 01, 2026, sold 5,000 shares in Oruka Therapeutics (ORKA) for $319,384. Following the Form 4 filing with the SEC, Sandler has control over a total of 236,984 common shares of the company, with 236,984 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000037/xslF345X05/form4.xml

$ORKA

Sectors49d ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.

$IBB$LGND$OGN$ORKA$XLV$XOMA